Denali Therapeutics Inc. Proceeds from Issuance of Convertible Preferred Stock
Denali Therapeutics Inc. (DNLI) reported Proceeds from Issuance of Convertible Preferred Stock of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2020-02-27
- Denali Therapeutics Inc. proceeds from issuance of convertible preferred stock for fiscal 2019 was $0.00.
- Denali Therapeutics Inc. proceeds from issuance of convertible preferred stock for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- Denali Therapeutics Inc. proceeds from issuance of convertible preferred stock for fiscal 2017 was $29.97M, a 90.02% decline from fiscal 2016.
- Denali Therapeutics Inc. proceeds from issuance of convertible preferred stock for fiscal 2016 was $300.37M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 12 month |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-27 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-27 |
| 2017-12-31 | $29.97M 10-K · filed 2020-02-27 |
| 2016-12-31 | $300.37M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |